Beaker
@complementlady.bsky.social
Complemtologist, lab geek, clinical immunologist, wife, mother and Beaker fan. #Complement,#Beaker, sterile inflammation
Import consideration for complement therapeutics.
As therapies for complement-mediated kidney disease evolve, infection prevention remains critical!!!
We summarize current evidence, infectious risks & prevention strategies to support safe implementation in practice.
@asnpublications.bsky.social
journals.lww.com/cjasn/abstra...
We summarize current evidence, infectious risks & prevention strategies to support safe implementation in practice.
@asnpublications.bsky.social
journals.lww.com/cjasn/abstra...
journals.lww.com
February 7, 2026 at 1:37 PM
Import consideration for complement therapeutics.
It is exciting both to see that data published and to know the drug is moving forward in Phase 3. Privilege to be part of the complement biomarker work. nam02.safelinks.protection.outlook.com?url=https%3A...
ScienceDirect.com | Science, health and medical journals, full text articles and books.
nam02.safelinks.protection.outlook.com
January 24, 2026 at 1:58 PM
It is exciting both to see that data published and to know the drug is moving forward in Phase 3. Privilege to be part of the complement biomarker work. nam02.safelinks.protection.outlook.com?url=https%3A...
Exciting to see this published; appreciate the granularity of the complement data Ionis presents “Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen”
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including IgA nephropathy and geographi…
nam02.safelinks.protection.outlook.com
February 1, 2025 at 3:00 AM
Exciting to see this published; appreciate the granularity of the complement data Ionis presents “Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen”
Registration is open for the ECN online symposium on complement and AMD #complement www.ecomplement.org/forum/feb-27...
ECN: Feb 27, 2025 - AMD
www.ecomplement.org
January 30, 2025 at 2:48 AM
Registration is open for the ECN online symposium on complement and AMD #complement www.ecomplement.org/forum/feb-27...
Reposted by Beaker
NIH funded research benefits your community even if it doesn’t (yet!) directly benefit you. Each $ invested in NIH yields significantly higher return on investment (average 254%) than the same $ invested in “defense”.
Call your reps: (202) 224-3121
www.unitedformedicalresearch.org/nih-in-your-...
Call your reps: (202) 224-3121
www.unitedformedicalresearch.org/nih-in-your-...
January 23, 2025 at 2:59 PM
NIH funded research benefits your community even if it doesn’t (yet!) directly benefit you. Each $ invested in NIH yields significantly higher return on investment (average 254%) than the same $ invested in “defense”.
Call your reps: (202) 224-3121
www.unitedformedicalresearch.org/nih-in-your-...
Call your reps: (202) 224-3121
www.unitedformedicalresearch.org/nih-in-your-...
I don’t see much #complementImmunology on here yet but if you have an interest in complement immunology, we are preparing for the first Collaborative Complement Congress of the Americas happening March 2025! Join us! medschool.cuanschutz.edu/rheumatology.... #immunology
Division of Rheumatology
medschool.cuanschutz.edu
November 16, 2024 at 9:53 PM
I don’t see much #complementImmunology on here yet but if you have an interest in complement immunology, we are preparing for the first Collaborative Complement Congress of the Americas happening March 2025! Join us! medschool.cuanschutz.edu/rheumatology.... #immunology